Lung cancer is the second most commonly diagnosed cancer in both men and women in the United States and the leading cause of all cancer deaths. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.1
1 Lung Cancer (Non-Small Cell) Detailed Guide. American Cancer Society. Retrieved from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf.
3 Surveillance Epidemiology and End Results Stat Fact Sheets: Lung and Bronchus. National Cancer Institute. Retrieved from: http://seer.cancer.gov/statfacts/html/lungb.html.
4 Subramanian J, Govindan R. Lung Cancer in Never Smokers: A Review. Journal of Clinical Oncology. 2007;25:561-570. Retrieved from: http://jco.ascopubs.org/content/25/5/561.short.
5 Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. Journal of Clinical Oncology. 2005;23(11):2556-68.
6 Epidermal Growth Factor Receptor (EGFR) Testing for Advanced Non-Small Cell Lung Cancer. Cancer.net. Retrieved from: http://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/epidermal-growth-factor-receptor-egfr-testing-advanced-non-small-cell-lung-cancer.
9 NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer. National Comprehensive Cancer Network. Retrieved from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
10 Keedy V, Termin S, Somerfield M, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology. 2011;29(15):2121-2127.